Related Experiment Video
Updated: Jun 9, 2026

In vitro Assessment of Aortic Regurgitation Using Four-Dimensional Flow Magnetic Resonance Imaging
Published on: February 25, 2022
Vascular Disease Prospective-Retrospective Observational Registry for Aortic Aneurysm and Peripheral Artery Disease
Ju Yeon Choi1,2, Tae Oh Kim3, Jun Gyo Gwon1
1Division of Vascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Insights
The VAPOR registry in Korea collects integrated data on peripheral artery disease (PAD) and aortic aneurysm (AA) to improve vascular care. This real-world evidence supports precision medicine and better patient outcomes for atherosclerosis.
Area of Science:
- Vascular Surgery
- Cardiovascular Research
- Epidemiology
Background:
- Peripheral artery disease (PAD) and aortic aneurysm (AA) are significant manifestations of systemic atherosclerosis.
- Despite shared risk factors and pathways, integrated long-term data for both conditions are limited in Korea.
- This data scarcity hinders real-world evidence generation and outcome evaluation for vascular diseases.
Purpose of the Study:
- To establish the Vascular disease Prospective-Retrospective Observational Registry (VAPOR) in Korea.
- To systematically collect clinical, imaging, and procedural data for patients with AA and PAD.
- To identify shared and disease-specific risk factors, evaluate outcomes, and support precision vascular medicine.
Main Methods:
- VAPOR is a mixed retrospective-prospective registry, initially single-centered with plans for multicenter expansion.
- It collects comprehensive data on patients diagnosed with AA and/or PAD.
- The registry is designed to facilitate risk stratification and the development of an interoperable vascular data infrastructure.
Main Results:
- As of April 15, 2026, VAPOR enrolled 5,249 patients (4,438 retrospective, 811 prospective).
- The cohort includes 2,193 patients with AA, 3,287 with PAD, and 231 with both conditions.
- Primary outcomes focus on major adverse cardiovascular and limb events, alongside aneurysm/procedure-related events.
Conclusions:
- The VAPOR registry offers a valuable real-world dataset for assessing treatment outcomes and long-term prognoses in patients with AA or PAD.
- Its integrated retrospective and prospective data, with multicenter expansion potential, is a significant advancement for Korean vascular surgery.
- VAPOR is poised to enhance evidence-based management and promote precision vascular care.
Purpose:
Peripheral artery disease (PAD) and aortic aneurysm (AA) are major manifestations of systemic atherosclerosis. Although they differ in pathophysiology and clinical presentation, they share common risk factors and overlapping biological pathways. However, long-term integrated data encompassing both conditions remain limited in Korea, constraining real-world evidence generation and outcome evaluation.
Materials And Methods:
To address this gap, the Vascular disease Prospective-Retrospective Observational Registry (VAPOR) was established as a mixed retrospective- prospective registry. VAPOR was initially implemented at a single coordinating center and was designed for stepwise expansion to multiple institutions. The registry systematically collects clinical, imaging, and procedural data from patients with AA and PAD. It aims to identify shared and disease-specific risk factors, evaluate outcomes, and apply established risk-stratification frameworks, thereby supporting the development of an interoperable vascular data infrastructure for precision medicine, quality benchmarking, and policy development.
Results:
As of April 15, 2026, VAPOR included 5,249 unique patients, comprising 4,438 patients in the retrospective cohort and 811 patients in the prospective cohort. The registry included 2,193 patients with AA and 3,287 patients with PAD; 231 patients had both AA and PAD. The primary outcomes are the incidence of major adverse cardiovascular events, major adverse limb events, and aneurysm- or procedure-related adverse events. Secondary outcomes include technical success, hemodynamic and imaging parameters, safety outcomes, and patient-centered endpoints.
Conclusion:
VAPOR provides a comprehensive real-world dataset for evaluating treatment outcomes and long-term prognoses in patients with AA or PAD. By integrating retrospective and prospective cohorts and establishing an infrastructure for multicenter expansion, VAPOR represents an important initiative in Korean vascular surgery and has the potential to enhance evidence-based management and advance precision vascular care.
Related Concept Videos
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Aneurysm II: Clinical Manifestations and Diagnostic Studies
Peripheral Artery Disease I: Introduction
Aortic Regurgitation III: Medical Management
Aneurysm III: Interprofessional Care